Skip to main content

Table 5 Threshold Evaluation of NT-proBNP

From: Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

  

Pre NT-proBNP

Post NT-proBNP

Day2 NT-proBNP

≤300 pg/mL

> 300 pg/mL

≤300 pg/mL

> 300 pg/mL

≤300 pg/mL

> 300 pg/mL

LVEF Change

 N

<  10% (N = 17)

13

4

13

4

6

11

 Row %

76.47

23.53

76.47

23.53

35.29

64.71

 Col %

68.42

80

65

100

75

68.75

 N

≥ 10% (N = 7)

6

1

7

0

2

5

 Row %

85.71

14.29

100

0

28.57

71.43

 Col %

31.58

20

35

0

25

31.25

 

Total

19

5

20

4

8

16

Strain Group

 N

< −17 (N = 10)

9

1

9

1

5

5

 Row %

90

10

90

10

50

50

 Col %

69.23

33.33

64.29

50

71.43

55.56

 N

≥ − 17 (N = 6)

4

2

5

1

2

4

 Row %

66.67

33.33

83.33

16.67

33.33

66.67

 Col %

30.77

66.67

35.71

50

28.57

44.44

 

Total

13

3

14

2

7

9

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us